How do GLP‑3 and GLP‑1 therapies compare in terms of indications and efficacy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

There is no such thing as "GLP-3" therapy in clinical medicine

The question appears to contain a fundamental error: GLP-3 (glucagon-like peptide-3) does not exist as a therapeutic class or medication. The evidence provided exclusively discusses GLP-1 receptor agonists and combination therapies (GLP-1/GIP dual agonists like tirzepatide, and investigational GLP-1/GIP/glucagon triple agonists).

What Actually Exists: GLP-1 Receptor Agonists

GLP-1 receptor agonists are established therapies with multiple FDA-approved indications 1, 2, 3:

Primary Indications

  • Type 2 diabetes mellitus: Glycemic control in adults with T2DM 4
  • Obesity/weight management: Adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities 3, 5
  • Cardiovascular risk reduction: Liraglutide and semaglutide are indicated to reduce major adverse cardiovascular events (MACE) in adults with T2DM and established CVD 4

Available GLP-1 Receptor Agonists

Short-acting agents (primarily postprandial glucose control) 4:

  • Exenatide (twice daily)
  • Lixisenatide (once daily)

Long-acting agents (fasting and postprandial glucose control) 4, 6:

  • Liraglutide (once daily): 1.8 mg for diabetes, 3.0 mg for obesity
  • Semaglutide (once weekly): 1.0 mg for diabetes, 2.4 mg for obesity; also available as oral formulation
  • Dulaglutide (once weekly)
  • Exenatide ER (once weekly)

Dual GIP/GLP-1 agonist 1, 2:

  • Tirzepatide (once weekly): Superior weight loss (15-20.9% at 72 weeks) and glycemic control compared to GLP-1 monotherapy

Comparative Efficacy

For Glycemic Control in Type 2 Diabetes

Tirzepatide demonstrates superior HbA1c reduction (mean -2.10%, 95% CI -2.47% to -1.74%) compared to all GLP-1 receptor agonists 7. Among GLP-1 monotherapies, semaglutide shows the greatest efficacy with HbA1c reduction of approximately -1.45% 8, followed by dulaglutide (-1.1%) and liraglutide 7, 8.

For Weight Loss

In patients without diabetes 9, 10:

  • Tirzepatide 15 mg: up to 17.8% weight loss (95% CI 16.3-19.3%) at 72 weeks
  • Semaglutide 2.4 mg: up to 13.9% weight loss (95% CI 11.0-16.7%) at 68 weeks
  • Liraglutide 3.0 mg: up to 5.8% weight loss (95% CI 3.6-8.0%) at 26 weeks

Investigational triple agonist retatrutide (GLP-1/GIP/glucagon) shows even greater weight loss of 22.1% (95% CI 19.3-24.9%) at 48 weeks 9, 10.

For Cardiovascular Outcomes

Only specific GLP-1 RAs have proven cardiovascular benefit 4, 6:

  • Liraglutide (LEADER trial): 13% relative risk reduction in MACE (RR 0.87,95% CI 0.78-0.97)
  • Semaglutide (SUSTAIN-6, SELECT trials): Significant MACE reduction in patients with and without diabetes
  • Dulaglutide (REWIND trial): Lower incidence of MACE-3

Lixisenatide showed cardiovascular safety but no benefit (ELIXA trial) 4.

Common Pitfalls

  1. Not all GLP-1 RAs have cardiovascular indications: Only liraglutide has an FDA indication specifically for cardiovascular risk reduction in T2DM with established CVD 4

  2. Gastrointestinal adverse events are dose-dependent and common (nausea 47-84%, vomiting, diarrhea) but usually manageable with slow titration 1, 3, 9

  3. Long-term therapy is required: Weight regain occurs after discontinuation (mean 11.6% regain of lost weight within 52 weeks) 3

  4. Cost and access remain significant barriers, particularly for non-diabetes indications 5, 11

If you intended to ask about a different comparison (e.g., GLP-1 vs. GIP/GLP-1 dual agonists, or different GLP-1 receptor agonists), please clarify the specific agents or therapeutic classes you wish to compare.

References

4
Guideline

clinical and investigative endocrinology and diabetes.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2018

8
Research

Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2025

Related Questions

What is the recommended management protocol for weight loss using glucagon‑like peptide‑1 (GLP‑1) receptor agonists in adults?
Is it safe for a patient on a GLP‑1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide, exenatide) to consume pumpkin seeds, and are there any dietary or gastrointestinal considerations?
Do one‑meal‑a‑day (OMAD) fasting or intermittent fasting affect glucagon‑like peptide‑1 (GLP‑1) and other appetite‑regulating hormones in the brain?
For a patient with severe obesity, hyperlipidemia, and prediabetes, which glucagon‑like peptide‑1 (GLP‑1) receptor agonist should I request for coverage under [INSURANCE_PLAN], and what ICD‑10‑CM diagnosis codes and HCPCS medication codes should be used to maximize approval?
How does Trulicity (dulaglutide) compare to other GLP‑1 receptor agonists in terms of HbA1c reduction and weight loss?
Which antibiotics are primarily eliminated hepatically (via liver or bile) rather than renally?
Which benzodiazepine has the fastest onset of action for rapid sedation?
In a patient with recent herpes zoster infection who did not receive antiviral therapy, whose lesions have healed with hyperpigmentation but now has persistent numbness and burning sensation, what is the diagnosis and appropriate treatment?
In a patient with renal failure, what antibiotic regimen is recommended for streptococcal infection?
When should lorazepam be used instead of alprazolam (Xanax) for anxiety, and what are the appropriate dosing guidelines?
Can Unisom (diphenhydramine or doxylamine) cause anxiety?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.